
    
      Multicenter, placebo-controlled, double-blind, randomized, parallel-group, Phase 2b study in
      pediatric subjects (aged greater than equal to 6 to less than 18 years of age) with TS.
      Following a 28-day Screening period and Baseline visit, eligible subjects will be randomized
      1:1 to receive either ecopipam hydrochloride (HCl) or matching placebo for a 12 week
      treatment period. Doses will be titrated up and down from target dose of 2 mg/kg/day. Follow
      Up visit will be conducted after the last dose of study medication.
    
  